Enliven Therapeutics

Enliven Therapeutics, Inc (ELVN) Tops Q3 EPS by 3c - StreetInsider

Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q3 EPS of ($0.48), $0.03 better than the analyst estimate of ($0.51).

Enliven Therapeutics Inc Reports Q3 2024 Net Loss Per Share of $

Enliven Therapeutics Inc, a clinical-stage precision oncology company, focuses on developing potentially first-in-class therapies to address ...

Enliven Therapeutics Reports Third Quarter Financial Results and ...

Enliven Therapeutics announces positive Phase 1 results for ELVN-001 in CML patients, with 44.4% response rate and strong safety profile.

Wilson Sonsini Advises Enliven Therapeutics on Merger with Imara

On October 13, 2022, Enliven Therapeutics, a clinical-stage precision oncology company focused on the discovery and development of ...

Enliven Therapeutics - Updates, News, Events, Signals & Triggers

News Insight Details ... Enliven Therapeutics announced positive proof of concept data from a Phase 1 clinical trial of ELVN-001 in CML, achieving an initial ...

Why Is Enliven Therapeutics Stock Trading Higher On Monday?

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments.

Enliven Therapeutics Announces Q1 Financial Results and ...

Enliven Therapeutics, Inc., a clinical-stage precision oncology company, announced significant progress in its pipeline and financial ...

Enliven Therapeutics Launches with Vision of Advancing Medicine ...

Enliven Therapeutics Announces Positive Data Update from Phase ...

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia ... BOULDER, Colo., Sept.

Enliven Therapeutics to Present at Two Upcoming Investor ... - WFLA

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help ...

Enliven Therapeutics Raises $90M in PIPE Financing

NEW YORK – Enliven Therapeutics on Tuesday said it has raised $90 million in a private investment in public equity (PIPE) financing to ...

Enliven Therapeutics Reports First Quarter Financial Results and ...

BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision ...

Enliven Therapeutics Inc. Profile - ELVN - MarketWatch

Biography. Anish Patel PharmD. Chief Operating Officer. Anish Patel founded Enliven Therapeutics, Inc. and Enliven Therapeutics, Inc. Dr. Patel holds the ...

Enliven Therapeutics Reports Third Quarter Financial Results and ...

, Nov. 13, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company ...

EnLiven Therapeutics – OrbiMed

EnLiven Therapeutics Nov 02, 2023 Share linkedin linkedin twitter twitter EN CH icon linkedin icon linkedin icon twitter icon twitter

ELVN - Enliven Therapeutics, Inc. Stock - Share Price, Short Interest ...

ELVN - Enliven Therapeutics, Inc. Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NasdaqGS)

Enliven Therapeutics to Present at Two Upcoming Investor ... - WJBF

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology ...

Enliven Therapeutics Other Current Liabilities 2020-2024 | ELVN

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The ...

Enliven Therapeutics Inc. Archives - BizWest

Enliven Therapeutics Inc. Enliven Therapeutics begins patient dosing in oncology drug trial. August 14, 2024 2:32:19 pm. Enliven has cash runway into late 2026.

April 24, 2024 Samuel Kintz Chief Executive Officer Enliven ...

Enliven Therapeutics, Inc. 6200 Lookout Road. Boulder, CO 80301. Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3. Filed April ...